Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2023-06-06 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰第二届监事会第七次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of a supervisory board meeting resolution by 百奥泰生物制药股份有限公司. It details the meeting date, attendance, and the approval of a proposal regarding the non-recurring profit and loss details for multiple years, including a verification report by an accounting firm. The document is short (853 characters) and primarily serves as a formal announcement of the meeting's decisions rather than containing full financial statements or detailed audit results. It does not present a full audit report but references an audit verification report. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement about supervisory board decisions and related audit verification, not the audit report itself or a full financial report.
2023-06-06 Chinese
百奥泰 2020年度、2021年度、2022年度及2023年1-3月非经常性损益明细表鉴证报告
Regulatory Filings
2023-06-06 Chinese
百奥泰 监事会关于公司2023年度向特定对象发行A股股票相关事项的书面审核意见
Regulatory Filings
2023-06-06 Chinese
百奥泰 独立董事关于第二届董事会第八次会议相关事项的独立意见
Regulatory Filings
2023-06-06 Chinese
百奥泰 关于参加2022年度生物制品专场集体业绩说明会的公告
Regulatory Filings Classification · 90% confidence The document is an announcement about the company's participation in a 2022 annual performance explanation meeting organized by the Shanghai Stock Exchange. It provides details about the meeting time, location, participants, and how investors can join and ask questions. The document references the 2022 annual report but does not contain the report itself or detailed financial data. It is essentially an invitation and information notice for an investor presentation event rather than the presentation or report itself. Therefore, it fits best under the category of Investor Presentation (IP). However, since it is an announcement about the meeting rather than the presentation materials themselves, it is more accurately classified as a Regulatory Filing (RNS) because it does not contain the actual presentation content or financial data, just the announcement of the event.
2023-05-31 Chinese
百奥泰 关于5%以上股东减持时间过半的进展公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from 百奥泰生物制药股份有限公司 regarding the progress of a shareholding reduction plan by shareholders holding more than 5% of the company's shares. It details the shareholders involved, the number of shares held before and after reduction, the reduction plan timeline, and risk disclosures. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory disclosure about a significant shareholder's transaction progress, specifically a reduction in shareholding. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2023-05-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.